EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System

David Barnidge, Dhananjay Sakrikar, Tadeusz Kubicki, Benjamin A Derman, Andrzej J Jakubowiak, Gabriella Lakos

The Journal of Applied Laboratory Medicine · 2025

DOI: 10.1093/jalm/jfae142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von David Barnidge und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Binding Site, part of Thermo Fisher Scientific, Rochester, MN, United States. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Myeloma Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic monoclonal antibodies (t-mAbs) may interfere with electrophoresis-based methods used to monitor multiple myeloma (MM), which can create inaccurate results. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is an alternative to gels distinguishing between endogenous M-proteins and t-mAbs based on molecular mass.

Methods

Serum samples (n = 109) from 34 MM patients receiving Dara-KRd were collected 14 or 28 days postdaratumumab administration. Samples were analyzed using the EXENT® Analyzer that combines automated immunopurification and MALDI-TOF MS for the isotyping and quantification of monoclonal immunoglobulins.

Results

Daratumumab was identified in 103 out of 109 samples (94.5%). In all IgGλ (n = 8), IgAκ (n = 8), and IgAλ (n = 2) patients, the M-protein and daratumumab were detected. Of the IgGκ patients (n = 18), 5 patients had a total of 6 samples where the M-protein was detected but daratumumab was not. There was no difference in the detection rate of daratumumab between samples taken 14 and 28 days postadministration with the median daratumumab concentration being 0.95 and 0.54 g/L, respectively. A precision study was also performed on 25 replicates containing 1 g/L daratumumab in serum where a coefficient of variation of 4.2% was observed as determined by the EXENT Analyzer.

Conclusions

The Immunoglobulin Isotypes (GAM: IgG, IgA, and IgM) for the EXENT Analyzer detected and distinguished a daratumumab kappa light chain peak from an M-protein light chain peak in MM patient serum when resolved by the mass spectrometer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, MonoclonalSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationMyeloma ProteinsAntineoplastic AgentsHumansMaleFemaleAgedMiddle AgedImmunoglobulin G

Substanzen

daratumumabAntibodies, MonoclonalMyeloma Proteinsmultiple myeloma M-proteinsImmunoglobulin GAntineoplastic Agents

Autor:innen und Institutionen

  • The Binding Site, part of Thermo Fisher Scientific, Rochester, MN, United States.
  • Biological Sciences Division, University of Chicago, Chicago, IL, United States.

Zitieren

APA

Barnidge, D., Sakrikar, D., Kubicki, T., Derman, B. A., Jakubowiak, A. J., & Lakos, G. (2025). Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae142

Vancouver

Barnidge D, Sakrikar D, Kubicki T, Derman BA, Jakubowiak AJ, Lakos G. Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfae142

BibTeX
@article{Barnidge2025,
  author = {Barnidge, David and Sakrikar, Dhananjay and Kubicki, Tadeusz and Derman, Benjamin A and Jakubowiak, Andrzej J and Lakos, Gabriella},
  title = {Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2025},
  doi = {10.1093/jalm/jfae142}
}
Kostenlos starten →